Feasibility of Integrating Panel-Based Pharmacogenomics Testing for Chemotherapy and Supportive Care in Patients With Colorectal Cancer.
Pashtoon Murtaza KasiTyler KoepErica SchnettlerFaisal ShahjehanVaishnavi KamathamCandice BaldeoCaren L HughesPublished in: Technology in cancer research & treatment (2020)
Preemptive comprehensive pharmacogenomics testing can be integrated into clinical practice in real-time for patients with cancer given faster turnaround and low cost. Pharmacist-driven, patient-specific medication management consults add further value given the number of genes/drugs. This sets the stage for a prospective randomized clinical trial to demonstrate the amount of benefit this can result in these patients.
Keyphrases
- low cost
- end stage renal disease
- clinical practice
- healthcare
- ejection fraction
- adverse drug
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- palliative care
- prognostic factors
- squamous cell carcinoma
- gene expression
- locally advanced
- quality improvement
- emergency department
- dna methylation
- radiation therapy
- patient reported outcomes
- rectal cancer
- health insurance
- drug induced
- chemotherapy induced